Hostname: page-component-cd9895bd7-jn8rn Total loading time: 0 Render date: 2024-12-25T19:00:27.988Z Has data issue: false hasContentIssue false
  • English
  • Français

Tardive dyskinesias and antipsychotics: a review

Published online by Cambridge University Press:  16 April 2020

Pierre-Michel Llorca ,
Isabelle Chereau ,
Frank-Jean Bayle  and
Christophe Lancon
Pierre-Michel Llorca*
Affiliation:
C.M.P.B, C.H.U. Clermont-Ferrand, rue Montalembert, BP 69, 63003 Clermont-Ferrand cedex 1, France
Isabelle Chereau
Affiliation:
C.M.P.B, C.H.U. Clermont-Ferrand, rue Montalembert, BP 69, 63003 Clermont-Ferrand cedex 1, France
Frank-Jean Bayle
Affiliation:
Université Paris V, René Descartes et CH Sainte Anne, Service Hospitalo-Universitaire, 1, rue Cabanis, 75674 Paris cedex, France
Christophe Lancon
Affiliation:
Hôpital Sainte Marguerite, 270, boulevard Sainte Marguerite, 13009 Marseille, France
*
*Corresponding author. Tel.: +33-4-73-75-21-24; fax: +33-4-73-75-21-26. E-mail address: pmlfllorca@aol.com (P.M. Llorca).
Get access

Summary

Currently, tardive dyskinesia (TD) remains an important clinical problem. The average prevalence is estimated at 30%. The appearance of antipsychotics has opened new paths. The extrapyramidal profile of these molecules is more favorable than that of conventional neuroleptics. In order to assess their prophylactic as well as curative potential, we reviewed the literature concerning four of these atypical antipsychotics: clozapine, risperidone olanzapine and amisulpride. Clozapine seems to induce fewer cases of TD than the conventional neuroleptics, and has a specific therapeutic effect. However, the risk of agranulocytosis reduces the possibility of utilisation. Risperidone appears to be an effective therapy, but several authors report cases of TD during treatment. Furthermore, larger studies and longer follow-ups are necessary to confirm the efficiency of olanzapine and amisulpride. Further studies and observations are still necessary before drawing any conclusion for these new atypical antipsychotic actions. They are doubtlessly promising, but we cannot ignore the notion of risk–benefit; regular monitoring and listening to the subjective experience of the patients must remain uppermost in the choice of therapy.

Keywords

Atypical antipsychoticsTardive dyskinesiasClozapineRisperidoneOlanzapineAmisulpride
Type
Review
Information
European Psychiatry , Volume 17 , Issue 3 , May 2002 , pp. 129 - 138
Copyright
Copyright © Éditions scientifiques et médicales Elsevier SAS. 2002

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Addington, DEToewes, JAAddington, JMRisperidone and tardive dyskinesia. J. Clin. Psychiatry 1995;56:484–5.Google ScholarPubMed
Ahmed, SChengappa, KNNaidu, VRBaker, RWParepally, HSchooler, NRClozapine withdraval - emergent dystonias and dyskinesias: a case series. J. Clin. Psychiatry 1988;59:472–7.CrossRefGoogle Scholar
Almeida Osvaldo, POlanzapine for the treatment of tardive dyskinesia. J. Clin. Psychiatry 7 July 1998;59:380–1.CrossRefGoogle Scholar
Anand, VSDewan, MJWithdraval-emergent dyskinesia in a patient on undergoing dosage reduction. Ann. Clin. Psychiatry 1996;8:179–82.Google Scholar
Bassit, DPLouza Neto, MRClozapine efficacy in tardive dys-kinesia in schizophrenic patients. Eur. Arch. Psychiatry Clin. Neurosc. (Germany) 1998;248(4):209–11.Google Scholar
Beasley, CMDellva, MATamura, RNMorgenstern, HGlazer, WMFerguson, KTollefson, GDRandomised double blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long term treatment with olanzapine or haloperidol. Br. J. Psychiatry 1999;174:23–30.CrossRefGoogle ScholarPubMed
Boyer, PLecrubier, YPoech, AJTreatment of positive and negative symptoms: pharmacologic approaches. In: Andreasen, NC editor. Schizophrenia: Positives and Negatives Symptoms and Syndromes, vol. 24. Basel, Switzerland: Karger; 2000. p. 152–74.Google Scholar
Brecher, M(abstract P-15-1)Long -term safety of risperidone. Eur. Neuropsychopharmacol. 1996;6(Suppl. 3):170.CrossRefGoogle Scholar
Brecher, MJeste, DOkamoto, ALow frequency of tardive dykinesia in elderly patients with dementia exposed to risperidone for up to one year, Presented at the 37th Annual Meeting of the American college of neuropsychopharmacology. Puerto Rico: San Juan; Dec. 14-18, 1998.Google Scholar
Buzan, RDRisperidone-induced tardive dyskinesia. Am. J. Psychiatry 1996;153:734–5.Google ScholarPubMed
Casey, DEEffects of clozapine therapy in schizophrenie individuals at risk for tardive dyskinesia. Clozapine : a treatment option to be realized. J. Clin. Psychiatry 1998;59(Suppl 3):31–7.Google Scholar
Casey, DETardive dykinesia and atypical drugs. Schizophr. Res. 1999;35:S61–6.Google Scholar
Chong Siow-Ann, MRemington, GTan, CRisperidone treatment of tardive dyskinesia and dystonia. J. Clin. Psychiatry 1999;60(5):340–1.CrossRefGoogle Scholar
Chouinard, GEffects of risperidone in Tardive Dyskinesia: Analysis of the Canadian Multicenter Risperidone Study. J. Clin. Psychopharmacol 1995;15(Suppl. 1):36–44.CrossRefGoogle ScholarPubMed
Cookell, AJSpencer, CMBenfield, PAmisulpride: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of schizophrenia CNS Drugs 1996;6:237–56.CrossRefGoogle Scholar
Dalery, Jd’Amato, TLa schizophrénie, recherches actuelles et perspectives. Masson; 1999.Google Scholar
Daniel, DGSmith, KHyde, TEgan, M(letter)Neuroleptic-induced tardive dyskinesia. Am. J. Psychiatry 1996;153: 734–734.Google ScholarPubMed
Danion, JMRein, WFleurot, OImprovement of schizophrenic patients with primary negative symptoms treated with Amisulpride. Am. J. Psychiatry 1999;156(4):610–6.Google ScholarPubMed
Factor, SAFriedman, JHThe emerging role of clozapine in the treatment of movement disorders. Mov. Disord. 1997;12: 483–96.CrossRefGoogle ScholarPubMed
Gerlach, JNew anti psychotics: classification, efficacy and adverse effects. Schizophr. Bull. 1991;17:289–309.Google Scholar
Glazer, WReview of the incidence studies of tardive dyskinesia associated with typical antipsychotics. J. Clin. Psychiatry 2000; 61(Suppl. 4):15–20.Google ScholarPubMed
Glazer, WExpected incidence of tardive dyskinesia associated with atypical antipsychotics. J. Clin. Psychiatry 2000;61(Suppl. 4):21–6.Google ScholarPubMed
Jeste, DVWyatt, RJTardive dyskinesia: Reversible and persistent. Arch. Gen. Psychiatry 1979;36(5):585–90.CrossRefGoogle ScholarPubMed
Jeste, DVLacro, JPBailey, ARockwell, EHarris, MJCaligiuri, MPLower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients. J. Am. Geriatr. Soc. 1999;47:716–9.Google ScholarPubMed
Jolley, AGHirsch, SRMcRink, AManchanda, RTrial of brief intermittent neuroleptic prophilaxis for selected schizophrenic outpatients: clinical out come at one year. Br. Med. J. 1989;298: 985–90.CrossRefGoogle Scholar
Kane, JMTardive dyskinesia. In: Jeste, DVWyatt, RJ editors. Neuropsychiatric Movement Disorders. Washington, DC: American Psychiaric Press; 1984. p. 68–95.Google Scholar
Kane, JMWoermer, MLieberman, JATardive dyskinesia: Prevalence, incidence, and risk factors. Psychopharmacology 1985;2(Suppl):72–8.Google Scholar
Kane, JMHonigfeld, GSinger, JClozapine for the treatment resistant schizophrenic: a double-blind comparison versus Chlopromazine/benztropine. Arch. Gen. Psychiatry 1988;45: 789–96.CrossRefGoogle Scholar
Kane, JMWoermer, MGPollak, SSafferman, AZLieberman, JADoes clozapine cause tardive dyskinesia? J. Clin. Psychiatry 1993;54:327–30.Google ScholarPubMed
Kane, JMTardive dyskinesia: epidemiological and clinical presentation. In: Bloom, FEKupfer, DJ editors. Psychopharmacology: The Fourth Generation of Progress. New York: Raven press; 1995. p. 1485–96.Google Scholar
Kane, JMTardive dyskinesia in affective disorders. J. Clin. Psychiatry 1999;60(Suppl. 5):43–7.Google ScholarPubMed
Keck, PMcElroy, SStrakowski, SSoutullo, CAntipsychotics in the treatment of mood disorders and risk of tardive dyskinesia. J. Clin. Psychiatry 2000;61(Suppl. 4):33–8.Google ScholarPubMed
Kopala, LCHoner, GWSchizophrenia and severe tardive dyskinesia responsive to risperidone. J. Clin. Psychopharmacol. 1994;14:430–1.CrossRefGoogle Scholar
Larach, Walters VZamboni, Tognolini RRueda, MHGallardo, HTorres, RDelisi, LETardive dyskinesia (TD) review and report on severe TD cases treated with clozapine, with 12, 8 and 5 years of video follow-up. Schizophr. Res. 1997;28: 231–46.Google ScholarPubMed
Lieberman, JASaltz, BLJohns, CAPollak, SBorenstein, MKane, JMThe effects of clozapine on tardive dyskinesia. Br. J. Psychiatry 1991;158:503–10.CrossRefGoogle ScholarPubMed
Littrell, KHJohnson, CGLittrel, SPeabody CD. Marked reduction of tardive dyskinesia with olanzapine. Arch. Gen. Psychiatry 1998;55:279–80.CrossRefGoogle ScholarPubMed
Loo, HPorier-littre, MFRein, WFleurot, OAmisulpride versus placebo in the long-term treatment of the negative symptomes of schizophrenia. Br J Psychiatry 1997;170:18–22.CrossRefGoogle Scholar
Lykouras, LYannakis, RHatzimanolis, JChristodoulou, GNTwo cases of risperidone-induced tardive dyskinesia and a review of the literature. Eur. Psychiatry 1999;14:245–7.CrossRefGoogle Scholar
Meltzer, HYClinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology 1989;99:18–27.Google ScholarPubMed
Modestin, JStephan, PLErni, TUmari, TPrevalence of extra pyramidal syndromes in psychiatric inpatients and the relationship of clozapine treatment to tardive dyskinesia. Schizophr. Res. 2000;42:223–30.CrossRefGoogle Scholar
Morgensten, HGlazer, WMIdentifying risk-factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medication. Arch. Gen. Psychiatry 1993;50:723–33.CrossRefGoogle Scholar
Newton, JECannon, DJCouch, LPaige, SRReid, GMSummers, BNEffects of repeated drug holidays on serum haloperidol concentration, psychiatric symptoms and movement disorders patients. J. Clin. Psychiatry 1989;50:132–5.Google Scholar
O’Brien, JBarber, RMarked improvement in tardive dyskinesia following treatment with olanzapine in a elderly subject. Br. J. Psychiatry 1998;172:186–9.CrossRefGoogle Scholar
Owens, DGCExtrapyramidal side effects and tolerability of risperidone: a review. J. Clin. Psychiatry 1994;55:29–35.Google ScholarPubMed
Palliere-Martinot, MLLecubrier, YMartinot, JLAubin, FImprovement of some schizophrenia deficit symptoms with low doses of amisulpride. Am. J. Psychiatry 1995;152:130–3.Google Scholar
Peacock, LSolgaard, TLublin, HGerlach, JClozapine versus typical anti psychotic: a retro and prospective study of extrapyramidal side effects. Psychopharmacology (Berlin) 1996;124: 188–96.CrossRefGoogle Scholar
Perrault, GSchoemaker, HScatton, BPlace de l’amisulpride dans la classe des neuroleptiques atypiques. L’Encephale 1996(Suppl. 11):3–8.Google Scholar
Rien, WTurjanski, SClinical update on amisulpride in deficit schizophrenia. Int. Clin. Psychopharmacol. 1997;12(Suppl. 2):S19–27.CrossRefGoogle Scholar
Sherr, JDThaker, GProgression of abnormal involuntary movements during risperidone treatment. J. Clin. Psychiatry 1998;59:478–9.CrossRefGoogle ScholarPubMed
Simpson, GLee, JHShrivastava, RKClozapine in tardive dyskinesias. Psychopharmacology 1978;56:75–80.Google Scholar
Simpson, GThe treatment of tardive dyskinesia ad tardive dystonia. J. Clin. Psychiatry 2000;61(Suppl. 4):39–44.Google Scholar
Sotullo, CAKeck, PEElroy, SMCOlanzapine in the treatment of tardive dyskinesia : A report of two cases. J. Clin. Psychop-harmacol. 1999;19(1):100–1.CrossRefGoogle Scholar
Speller, JC Barnes TRE, Curson, DAPantelis, CAlberts, JLOne year, low-dose neuroleptic study of inpatients with chronic schizophrenia characterised by persistent negative symptoms. Amisulpride versus Haloperidol. Br. J. Psychiatry 1997;171: 564–8.CrossRefGoogle Scholar
Tamminga, CAThaker, GKMoran, MKakigi, TGao, XMClozapine in tardive dyskinesia: observations from human and animal studies. J. Clin. Psychiatry 1994;55(9 Suppl. B):120–6.Google Scholar
Tollefson, GDBeasley, CMTran, PV(abstact)Olanzapine versus haloperidol: results of multicenter, international trial. Schizophr. Res. 1996;18:131.Google Scholar
Waddington, JLTardive dyskinesia in schizophrenia and other disorders: Association with aging, cognitive dysfunction, and structural brain pathology in relation to neuroleptic exposure. Hum. Psychopharmacol. 1987;2:11–22.Google Scholar
Woerner, MGSheitman, BBLieberman, JAKane, JMTardive dyskinesia induced by risperidone? Am. J. Psychiatry 1996;153:843.Google ScholarPubMed
Wolf, MAWertenschlad, NFacteurs de risque et prévention des dyskinésies tardives. Can. J. Psychiatry 1989;34:177–81.CrossRefGoogle Scholar
Wolf, MAYassa, RLlorca, PMNeuroleptic-induced movement disorders: historical perspectives. In: Yassa, RNair, NPVJeste, D editors. Neuroleptic-inducted Movement Disorders: A Comprehensive Survey. Cambridge University Press; 1997. p. 3–9.Google Scholar
Wolf, MALes dyskinésies tardives. Mosaique 2000;11:5–10.Google Scholar
Yassa, RJeste, DVGender differences in tardive dyskinesia: a critical review of the literature. Schizophr. Bull. 1992;18(4): 701–15.Google ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.